Nebulized drug for lung metastases from solid tumors
Part of Cancer, Infections, Lungs & breathing clinical trials.
This study tests a new drug given as a mist you breathe in, for people whose cancer has spread to the lungs. The goal is to see if it can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced non-small cell lung cancer or another solid tumor that has spread to the lungs.
- Standard treatments (like chemotherapy, immunotherapy, or targeted therapy) have either failed, are not available, or are not suitable for you.
- Your cancer can be measured with imaging (CT or MRI).
- Your breathing function is good enough (at least half of the expected lung capacity).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called YL202 for people with advanced solid tumors (cancers that have spread or cannot be removed). It aims to see if the drug can shrink tumors or slow cancer growth. You may be able to join if you have certain types of cancer, have not had a previous HER3 treatment, and can provide a tumor sample.
This trial tests YL201 in people with advanced (late-stage) solid cancers when usual treatments don’t work or can’t be tolerated. The study looks at how the treatment is given, how safe it is, and how well it can shrink tumors.
This trial tests a new drug, XTX501, for people with advanced non-small cell lung cancer or other solid tumors. It aims to see if the drug can help shrink tumors or slow their growth.
This early-stage trial tests a new drug called JH021 in people with advanced cancer that has stopped responding to standard treatments. The drug may help patients with certain lung cancers (NSCLC with specific EGFR mutations) or other solid tumors grow back after other therapies have failed.
This trial tests a combination of two drugs, tislelizumab (an immunotherapy) and SYS6010, for people with advanced non-small cell lung cancer whose cancer has gotten worse after prior immunotherapy. It aims to see if this new combination can help when standard treatments have stopped working.
This trial tests a new injection, YH02, directly into tumors for people with advanced solid tumors (like head and neck, breast, or melanoma) that are no longer responding to standard treatments. The goal is to see if it can shrink tumors or slow disease progression.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.